Anti-Human VE-Cadherin – CF®633
Anti-Human VE-Cadherin – CF®633
Product No.: V134CF
[product_table name="All Top" skus="V134"]
- -
- -
| Target VE-Cadherin Product Type Polyclonal Antibody Alternate Names Vascular Endothelial Cadherin, Cadherin-5 (CDH5), 7B4, CD144, VE-Cad, VEC |
- -
- -
| Select Product Size | Qty Max: Min: 1 Step: 1 Select A Size |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Goat Immunogen NS0-Derived Recombinant Human VE-Cadherin Extracellular Domain Product Concentration 0.2 mg/ml Formulation This CF®633 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This CF®633 conjugate is stable when stored at 2-8°C, protected from light. Do not freeze. Country of Origin USA Shipping 2-8°C Excitation Laser 633 nm or 635 nm Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. Emission Max 630/650 nm DescriptionDescriptionSpecificity Goat Anti-Human Vascular Endothelial Cadherin (VE-Cadherin) recognizes Human VE-Cadherin. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research. Background Vascular endothelial-cadherin (VE-Cadherin) also known as cadherin-5 is an endothelial specific, homophilic adhesion molecule located at the lateral cell surface.1 VE-Cadherin is crucial for the proper assembly of vascular structures and the maintenance of vascular integrity.2 It plays a pivotal role in the formation, maturation and remodeling of the vascular wall.3 VE-cadherin is a positive and endothelial cell-specific regulator of transforming growth factor-beta (TGF-beta) signaling. Therefore, the reduction or inactivation of VE-cadherin may contribute to progression of diseases where TGF-beta signaling is impaired.4 PubMed NCBI Gene Bank ID UniProt.org References & Citations1. Vestweber, D. et al. (1997) J Cell Sci. 110: 583 2. Lambert, O. et al. (2008) Biochem Soc Trans. 36: 189 3. Gavard, J. et al. (2009) FEBS Lett. 583: 1 4. Dejana, E. et al. (2008) EMBO J. 27: 993 |
Related Products
- -
- -
Prod No. | Description |
|---|---|
| V172 | |
| V148 | |
| V134 | |
| C1362 | |
| C1370 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
